Newsroom
Sorted by: Latest
-
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing The New Wave of Psychedelics” at 4:30pm ET. A live audio webcast of the fireside chat will be accessible from the “E...
-
Regis Corporation Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year 2026
MINNEAPOLIS--(BUSINESS WIRE)--Regis Corporation (NasdaqGM: RGS), a leader in the haircare industry, today announced financial results for the fourth fiscal quarter and full year ended June 30, 2026. Susan Lintonsmith, Regis Corporation's President and Chief Executive Officer, commented, "Fiscal 2026 marked a year of continued progress toward strengthening the foundation of our business. We delivered revenue of $224.5 million, operating income of $24.4 million, Adjusted EBITDA of $32.8 million,...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - September 31.08.2026 QSEP.LN IE000FQ808R5 350,002.00 USD 8,781,254.33 25.089 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Global Aerospace & Defence UCITS ETF 31.08.2026 MISL.LN IE000NVDQXE1 4,525,002.00 USD 155,316,816.72 34.324 ...
-
Xtrackers UK Regulatory Announcement: IMPORTANT NOTICE TO SHAREHOLDERS OF XTRACKERS
LONDON--(BUSINESS WIRE)-- Xtrackers Investment Company with Variable Capital Registered office: 17, Boulevard de Kockelscheuer, L-1821 Luxembourg R.C.S. Luxembourg B-119.899 (the “Company”) IMPORTANT NOTICE TO SHAREHOLDERS OF: Xtrackers MSCI USA Swap UCITS ETF (ISIN: LU0274210672) Xtrackers MSCI Taiwan UCITS ETF (ISIN: LU0292109187) Xtrackers Nifty 50 Swap UCITS ETF (ISIN: LU0292109690) Xtrackers MSCI Korea UCITS ETF (ISIN: LU0292100046) Xtrackers MSCI China A UCITS ETF (ISIN: LU0292109856) Xt...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share FIRST TRUST BLOOMBERG GLOBAL SEMICONDUCTOR SUPPLY CHAIN UCITS ETF 31.08.2026 CHPS.LN IE000KXTLDE2 775,002.00 USD 36,833,747.20 47.527 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Momentum UCITS ETF 31.08.2026 FTMO.LN IE000CY30YV9 3,100,002.00 USD 95,006,858.57 30.647 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - May 31.08.2026 GMAY.LN IE000P0FL8E3 1,350,002.00 USD 54,969,984.53 40.718 ...
-
Samenvatting: Fujirebio breidt in Canada toegang tot op bloed gebaseerde neurologietesten uit met Class II MDL's van Health Canada voor de Lumipulse® G NfL Blood- en Lumipulse G pTau 217 Plasma-testen
GENT, België & TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. en Fujirebio, zijn dochteronderneming volledig in handen van het bedrijf, maakten vandaag bekend dat Health Canada Class II MDL's (Medical Device Licenses) heeft toegekend voor de Lumipulse G NfL Blood- en de Lumipulse G pTau 217 Plasma-test voor gebruik op het volledig geautomatiseerde LUMIPULSE® G immunoassay-platform in de Canadese markt. "De goedkeuring van de Lumipulse G NfL Blood- en Lumipulse G pTau 217 Plasma-testen voor kl...
-
Fujirebio baut Marktzugang in Kanada zu blutbasierten neurologischen Tests durch Lizenz für Medizinprodukte der Klasse II von Health Canada für Lumipulse® G NfL-Bluttests und Lumipulse G pTau 217 Plasma-Assays aus
GHENT, Belgien und TOKIO--(BUSINESS WIRE)--H.U. Group Holdings Inc. und ihre 100-prozentige Tochtergesellschaft Fujirebio gaben heute bekannt, dass Health Canada Lizenzen für Medizinprodukte der Klasse II (MDL) für den Lumipulse G NfL-Bluttest und den Lumipulse G pTau 217 Plasma-Assay für den Einsatz auf der vollautomatischen LUMIPULSE® G Immunoassay-Plattform auf dem kanadischen Markt erteilt hat. „Die Zulassung des Lumipulse G NfL-Bluttests und des Lumipulse G pTau 217 Plasma-Assays für den k...